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httpIntroduction: Abdominal aortic aneurysm (AAA) screening programmes reduce AAA-related mortality and are
cost-effective. This study aims to assess the state and variability of AAA screening programmes worldwide.
Methods: Data were obtained from an international expert group convened at the 34th Charing Cross
Symposium as well as government websites and published reports on screening programmes.
Results: Six countries are in the process of implementing national AAA screening programmes, with Italy still
performing screening trials. There is wide variability in inclusion criteria between countries with the majority
screening only men in their 65th year, however 3 programmes include women, 2 programmes only include
patients with high cardiovascular risk, and 2 trials are also screening for hypertension and lower limb
atherosclerosis. Surveillance intervals vary between screening programmes, with the most common regimen
being to vary the surveillance interval depending upon aneurysm size, however the optimum surveillance interval
in terms of decreasing mortality and cost effectiveness remains uncertain.
Discussion: International dissemination of current AAA screening programme outcomes is required to inform
developing programmes about optimum screening intervals, beneﬁts of surveillance of the subaneurysmal aorta,
and screening for other cardiovascular disease.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Abdominal aortic aneurysms (AAA) are responsible for
approximately 7000 deaths per annum in England and
Wales, principally due to aneurysm rupture. Since the
mortality rate of AAA repair is reduced by a factor of
10 when performed electively rather than as an emergency,
detecting and treating AAA prior to rupture is clinically
beneﬁcial. Randomized controlled trials (RCTs) have
demonstrated that screening asymptomatic men over
65 for AAA reduces AAA-related mortality. These beneﬁts
remain signiﬁcant at both 7-1 and 10-year2 follow up.
Several studies have determined that screening for AAA is
cost-effective.3-5 The Health Technology Assessment is also
currently undertaking a report into the cost-effectiveness of
AAA screening in the UK, taking the decreasing incidence of
AAA into account. Their preliminary results (unpublished
data) suggest that screening remains cost-effective at the
current reported incidence of 1.7%. The evidence thereforeTo access continuing medical education questions on this paper,
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prevent deaths. Despite this only a handful of developed
countries worldwide have invested in national screening
programmes. The aim of this study was to assess the state
and variability of AAA screening programmes worldwide.
METHODS
Data were obtained from an international expert group
convened at the 34th Charing Cross symposium, speciﬁcally
to determine the uptake and delivery of AAA screening
worldwide. A standardised study proforma was given to all
senior members of the expert group. The proforma asked
about whether a national screening programme was
running within the country, the population covered by
screening, the method used to image the aorta, the aortic
diameter considered to be aneurysmal, the aortic diameter
at which patients were referred to a vascular surgeon, the
frequency of surveillance, the start date of the programme,
the total number of patients screened, the age and gender
of participants screened, the incidence of AAA within the
programme, and the mortality from repair of screen-
detected aneurysms. The responses were collated by PS and
ND. Additional data was obtained from published reports
on screening programmes that took place in the countries
which responded. Additional countries with screening pro-
grammes which did not have a representative at the
meeting were reviewed through their respective govern-
ment websites and published reports. Details relating to any
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trials were also collected from the www.clinicaltrials.gov
website.RESULTS
Completed proformas were returned by all countries
which had representatives attending the meeting, including
Denmark, England, Finland, Italy, New Zealand, Norway,
Scotland, Sweden, Wales and Western Australia. Data on
screening programmes in the USA and Northern Ireland was
obtained from government websites. A summary of the
aggregated data is shown in Table 1.State of screening programmes
Sweden, England, Scotland, Wales, Northern Ireland and the
USA have implemented or are in the process of implementing
nationwide AAA screening programmes. Finland has only
conducted cost-effectiveness modelling (concluding that one-
time AAA screening for men at the age of 65 is more cost-
effective than offering no screening at all). Both Denmark
(ClinicalTrials.gov NCT00662480) and Norway (NCT01248533)
have ongoing randomised controlled trials (RCTs) looking at
the impact of screening on all-cause mortality however the
Norway trial is limited toOslo. Both studies are simultaneously
screening for hypertension and lower limb atherosclerosis and
also look at the incidence of cardiovascular events as
a secondary outcomemeasure. In Italy, screening has begun in
Genoa only but it is unclearwhether this is an RCTor a regional
screening programme (noNCTnumberavailable). Netherlands
also started a trial in July 2012 (NCT01643317, data unavail-
able). Outside Europe, Western Australia completed an RCT
between 1996 and 1998 but has not continued surveillance,Table 1. Comparison of aneurysm screening programmes and trials w
Country Start
date
trial
End
date
trial
National screening
implemented
Population
screened
in trial
Western Australia 1996 1998 No 12 203
Denmark (2 trials) 1994
2008
1995
2010
No 4843
25 000
England (2 trials) 1997
1988
1999
1994
Yes started 2009 27 147
5394
Finland* N/A N/A No N/A
Norway 2011 2029 Oslo only N/A
New Zealand 2012 Ongoing No 2000
Scotland N/A N/A Yes started July 2012 N/A
Sweden N/A N/A Yes started 2006 N/A
Italy 2007 Ongoing No 8234
Wales N/A N/A Due to start 2012 N/A
Northern Ireland N/A N/A Yes started July 2012 N/A
USA (Society for
Vascular Surgery
guidelines)
2007 2008 Recommends if ever
smoked >100
cigarettes
2918
* Finland evaluated the cost-effectiveness of screening, but have notand New Zealand has recently started to offer aneurysm
screening, however, the geographical coverage of the pro-
gramme was not documented.Screening criteria
All countries perform screening for men, with the USA, New
Zealand and Italy also screening women. All countries
screen individuals in their 65th year or older, with New
Zealand only screening subjects with high cardiovascular
risk, and the USA only screening ever smokers.Aortic measurement and deﬁnitions
All screening programmes use a single ultrasound scan
to determine aortic diameter. All countries deﬁne the
minimum diameter for an aneurysm as 30 mm. Some
Swedish counties, Oslo and USA also include subjects with
subaneurysmal aortic dilatation (25e29 mm) in their
surveillance programme, offering them a repeat scan after
5 years.Surveillance interval
There is marked variation in surveillance frequency between
countries (Table 2). The most common regimen is to vary the
surveillance interval depending upon aneurysm size,
however, there is an agreement that the optimum surveil-
lance interval in terms of decreasing mortality and cost
effectiveness remains uncertain.Aneurysm prevalence and incidence
The prevalence of AAA in older men detected through pop-
ulation screening has varied from 7% in Western Australiaorldwide.
Population
covered by
screening
programme
Total
screened
thus far
Age group invited Gender
N/A 12 203 65e79 years Male
N/A 29 843 65e74 years Male
51 000 000 52 000 65th year
(65e74 years in trial)
Male
N/A N/A N/A N/A
2000/year 1116 65 years Male
300 000 250 High cardiovascular risk Male and
Female
5 200 000 Unknown 65th year Male
8 100 000 Attendance
rate 85%
65 years
(65e74 years in trial)
Male
N/A 8234 65 years and over Male and
Female
2 900 000 N/A 65th year Male
1 800 000 Unknown 65th year Male
311 000 000 Unknown 60e85 years Male
60e85 years Female
with cardiovascular risk
Over 50 if family history
Male and
Female
yet begun national screening.
Table 2. Worldwide surveillance intervals for population aneurysm screening.
Country What diameter
is considered
an aneurysm
What size is referred
for consideration
of surgery
Prevalence of AAA
in subjects undergoing
screening
Surveillance
interval
Mortality
from repair of
screen-detected
aneurysms
Western
Australia
30 mm 50 mm 30 mm 7%  55 mm 2.5% 6e12 monthly 65e74 year
men 2.5%
Denmark 30 mm 50 mm (but
not considered
for surgery
until 55 mm)
3.3% Annually (2e4 times
annually if þ55 mm)
1.5%
England 30 mm 55 mm 1.7% 30e44 mm yearly
45e54 mm 3 monthly
0.77%
Norway 30 mm 55 mm 3.4% 25e29 mm after 5 years
30e40 mm every 2 years
40e45 mm yearly
>45 mm every
3e6 months
0%
New
Zealand
30 mm 55 mm Pilot 8.9% in high
cardiovascular
risk males >65 years
Annually Unknown
Scotland 30 mm 55 mm Unknown 30e44 mm yearly
45e54 mm 3 monthly
Unknown
Sweden 30 mm however
many counties
offer a 5 year
follow up scan
if 25e29 mm
55 mm 1.7% þ 0.5% already
known outside
of programme
25e29 mm after 5 years
30e39 mm every 2 years
40e44 mm yearly
45e50 mm 6 monthly
50e55 mm 3 monthly
0%
Italy 30 mm 50 mm 6.2% 6 monthly 0.61%
Wales 30 mm 55 mm Unknown 30e44 mm yearly
45e54 mm 3 monthly
Unknown
Northern
Ireland
30 mm 55 mm Unknown 30e44 mm yearly
45e54 mm 3 monthly
Unknown
USA 30 mm 50 mm Unknown 26e29 mm 5 yearly
30e34 mm 3 yearly
35e44 mm 12 monthly
45e54 mm 6 monthly
Unknown
P.W. Stather et al. 233(1996e1998) to 1.7% in both England and Sweden (2010e
2011). New Zealand reports an early incidence of 8.9% in
subjects of high cardiovascular risk (2012). Mortality from
aneurysm repair of screen-detected aneurysms ranged from
0% in Norway and Sweden to 2.5% in Western Australia.
CONCLUSION
Although AAA screening has consistently been shown to
be cost-effective in reducing aneurysm-related mortality,
the instigation of national AAA screening programmes
remains sparse. A number of factors such as up-front costs,6
ultrasonographer training, database development, and
geographical distribution of ultrasonographers are signiﬁ-
cant barriers to the introduction of national AAA screening.
Countries considering AAA screening programmes could
usefully beneﬁt from the experience of existing pro-
grammes in other countries, allowing more cost-effective
screening to take place For example a recent report from
the USA found over a quarter of individuals screened for
AAA were referred inappropriately, either on the basis of
age or sex.7 It is imperative that existing national AAA
screening programmes publish the successes and short-comings of their programmes, to add to the existing reports
from the UK,1e2 USA,8 Denmark9 and Australia.10 Further
information from existing programmes is required on the
results of different screening models, the outcome of
rescanning the subaneurysmal aorta, optimum screening
intervals, mortality rates, and the outcome of screening for
additional conditions such as peripheral vascular disease.
ACKNOWLEDGEMENTS
The meeting of the expert group occurred at the 34th
Charing Cross symposium.Within the symposium the expert
group which convened to discuss the international varia-
tions in AAA screening were not directly funded, although
the meeting was funded by Pyramid Ltd and Bolton
Medical. The authors would like to thank the members of
the expert group, Anders Albäck, Martin Björck, Hector
Campbell, Edward Choke, Gillian Cockerill, Louis Fligelstone,
Matthew Glover, Roger Greenhalgh, Shervanti Homer-Van-
niasinkam, Jørgen Jørgensen, Sani Laukontaus, Jes Lindholt,
Paul Norman, Domenico Palombo, Janet Powell, Simon
Thompson, Andre van Rij, Maarit Venermo, and Anders
Wanhainen for making this data available.
234 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 3 March/2013FUNDING
PWS is funded by a fellowship from the Royal College of
Surgeons/Dunhill Medical Trust. ND is funded by a NIHR
academic clinical fellowship. MJB is supported by a HEFCE
Clinical Senior Lecturer Fellowship, The Leicester NIHR
Cardiovascular Biomedical Research Unit and The Circula-
tion Foundation President’s Early Career Award. TAL is
employed by Newcastle upon Tyne Hospitals NHS Trust
which receives funding for his work as regional advisor to
the NHS abdominal aortic aneurysm screening programme.CONFLICTS OF INTEREST
Nil.
REFERENCES
1 Kim LG, Scott RA, Ashton HA, Thompson SG. Multicentre
Aneurysm Screening Group. A sustained mortality beneﬁt from
screening for abdominal aortic aneurysm. Ann Intern Med
2007;146(10):699e706.
2 Thompson SG, Ashton HA, Gao L, Scott RA.Multicentre Aneurysm
Screening Group. Screening men for abdominal aortic aneurysm:
10 year mortality and cost-effectiveness results from the Multi-
centre Aneurysm Screening Study. BMJ 2009;338:b2307.
3 Sogaard R, Lausten J, Lindholt JS. Cost effectiveness of
abdominal aortic aneurysm screening and rescreening in menin a modern context: evaluation of a hypothetical cohort using
a decision analytical model. BMJ 2012;345:e4276.
4 Giardina S, Pane B, Spinella G, Cafueri G, Corbo M, Brasseur P,
et al. An economic evaluation of an abdominal aortic aneurysm
screening program in Italy. J Vasc Surg 2011;54(4):938e46.
5 Spronk S, van Kempen BJ, Boll AP, Jorgensen JJ, Hunink MG,
Kristiansen IS. Cost-effectiveness of screening for abdominal
aortic aneurysm in the Netherlands and Norway. Br J Surg
2011;98(11):1546e55.
6 Leger AS, Spencely M, McCollum CN, Mossa M. Screening for
abdominal aortic aneurysm: a computer assisted cost-utility
analysis. Eur J Vasc Endovas Surg 1996;11:183e90.
7 Lees ES, Pickett E, Hedayati N, Dawson DL, Pevec WC.
Implementation of an aortic screening program in clinical
practice: implications for the Screen for Aortic Aneurysms Very
Efﬁciently (SAAVE) Act. J Vasc Surg 2009;49(5):1107e11.
8 Chun KC, Teng KY, Van Spyk EN, Carson JG, Lees ES. Five-year
outcomes of an abdominal aortic aneurysm screening program
at a regional Veterans Affairs healthcare system. J Vasc Surg
2012 [epub ahead of print].
9 Lindholt JS, Sorensen J, Sogaard R, Henneberg EW. Long-term
beneﬁt and cost-effectivess analysis of screening for abdominal
aortic aneurysms from a randomized controlled trial. Br J Surg
2010;97:826e34.
10 Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT,
Spencer CA, Tuohy RJ, et al. Population based randomised
controlled trial on impact of screening on mortality from
abdominal aortic aneurysm. BMJ 2004;329(7477):125.
